Baudax Bios TI168 Receives Orphan Drug Designation for Hemophilia A with Inhibitors

Best Stocks2023-09-28

Unique Version: On September 28, 2023, Baudax Bio announced that their drug, TI-168, has received orphan drug designation from the FDA for the treatment of hemophilia A with inhibitors. Hemophilia A ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2370771770?lang=en_US&edition=fundamental","thumbnail":"https://beststocks.com/wp-content/uploads/2022/02/Vertex-Pharmaceuticals-Stock-750x365.png","is_english":true,"pubTime":"2023-09-28 20:09","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2370771770","market":"us","top_or_hot":-1,"title":"Baudax Bios TI168 Receives Orphan Drug Designation for Hemophilia A with Inhibitors","media":"Best Stocks","content":"<div>\n<p>Unique Version:\nOn September 28, 2023, Baudax Bio announced that their drug, TI-168, has received orphan drug designation from the FDA for the treatment of hemophilia A with inhibitors. Hemophilia A ...</p>\n\n<a href=\"https://beststocks.com/baudax-bios-ti168-receives-orphan-drug-design/\">Source Link</a>\n\n</div>\n","source":"beststocks_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Baudax Bios TI168 Receives Orphan Drug Designation for Hemophilia A with Inhibitors</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBaudax Bios TI168 Receives Orphan Drug Designation for Hemophilia A with Inhibitors\n</h2>\n\n<h4 class=\"meta\">\n\n\n2023-09-28 20:09 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://beststocks.com/baudax-bios-ti168-receives-orphan-drug-design/><strong>Best Stocks</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Unique Version:\nOn September 28, 2023, Baudax Bio announced that their drug, TI-168, has received orphan drug designation from the FDA for the treatment of hemophilia A with inhibitors. Hemophilia A ...</p>\n\n<a href=\"https://beststocks.com/baudax-bios-ti168-receives-orphan-drug-design/\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4021","symbol_name":"海运","start_time":0,"source_url":"https://beststocks.com/baudax-bios-ti168-receives-orphan-drug-design/","article_id":"2370771770","we_media_id":null,"thumbnails":["https://beststocks.com/wp-content/uploads/2022/02/Vertex-Pharmaceuticals-Stock-750x365.png"],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2370771770","pubTimestamp":1695902964,"sourceInfo":{"source_id":"beststocks_highlight","name":"Best Stocks"},"weMediaInfo":null,"summary":"On September 28, 2023, Baudax Bio announced that their drug, TI-168, has received orphan drug designation from the FDA for the treatment of hemophilia A with inhibitors. Hemophilia A is an uncommon genetic bleeding disorder caused by a mutation in the gene responsible for producing factor VIII , a crucial protein for blood clotting. In some individuals with hemophilia A, inhibitors, which are antibodies, can develop and complicate the management of bleeding episodes.TI-168, developed by Baudax Bio, shows promising potential as a treatment for hemophilia A with inhibitors. The company is confident in its ability to initiate the Phase 1/2a Clinical Trial for TI-168 with a reasonable initial budget.Under the Orphan Drug Act, the FDA has the authority to grant orphan designation to drugs or biological products designed to treat rare diseases or conditions. Rare diseases are generally defined as those that affect fewer than 200,000 individuals in the United States. By granting orphan drug d","collect":0,"end_time":0,"defaultTopTitle":"beststocks.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4021":"海运","BXRX":"Baudax Bio, Inc.","NM":"Navios海事控股","BK4007":"制药"},"translate_title":"Baudax Bios TI168获得孤儿药指定，用于治疗血友病A和抑制剂","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"BXRX":1,"NM":1},"content_text":"Unique Version:\nOn September 28, 2023, Baudax Bio announced that their drug, TI-168, has received orphan drug designation from the FDA for the treatment of hemophilia A with inhibitors. Hemophilia A is an uncommon genetic bleeding disorder caused by a mutation in the gene responsible for producing factor VIII (FVIII), a crucial protein for blood clotting. In some individuals with hemophilia A, inhibitors, which are antibodies, can develop and complicate the management of bleeding episodes.\nTI-168, developed by Baudax Bio, shows promising potential as a treatment for hemophilia A with inhibitors. The company is confident in its ability to initiate the Phase 1/2a Clinical Trial for TI-168 with a reasonable initial budget.\nUnder the Orphan Drug Act, the FDA has the authority to grant orphan designation to drugs or biological products designed to treat rare diseases or conditions. Rare diseases are generally defined as those that affect fewer than 200,000 individuals in the United States. By granting orphan drug designation, the FDA provides certain incentives, including tax credits and exclusivity, to promote the development of drugs for rare diseases.\n\n\n\n\n\n\n\n\n\n\n\n\nBaudax Bio, Inc.\n        BXRX\nNeutral\n\nUpdated on: 28/09/2023\n\n\n\nFinancial Health\n\n\nWeak                \n\n\n\n                    Debt to equity ratio: Sell                \n\n\n                    Price to earnings ratio: Neutral                \n\n\n                    Price to book ratio: Neutral                \n\n\n                    DCF: Strong Buy                \n\n\n                    ROE: Strong Buy                \n\nShow more\n\n\nPrice Target\n\n\n                    Current $0.30\n\n\n\n                    Concensus $0.00\n\n\n\n\n                    Low $0.00\n\n\n\n                    Median $0.00\n\n\n\n                    High $0.00\n\n\n\nShow more\n\n\nSocial Sentiments\nWe did not find social sentiment data for this stock\n\n\nAnalyst Ratings\nThere are no analysts data to display\n\n\n\nBXRX Stock Performance on September 28, 2023: Impressive Earnings Growth but Caution Advised for Investors\n BXRX Stock Performance on September 28, 2023\nOn September 28, 2023, BXRX stock had a previous close of $0.31 and opened at the same price. Throughout the day, the stock fluctuated within a range of $0.30 to $0.32. The trading volume for the day was 190,537 shares. The market capitalization of BXRX stands at $3.2 million.\nBXRX has shown impressive earnings growth in the past year, with a growth rate of +56.27%. This year, the company’s earnings growth has been even more remarkable, reaching +98.86%.\nThe revenue growth for BXRX in the last year was +17.50%. However, it is important to note that BXRX reported an annual profit of -$58.8 million, resulting in a net profit margin of -4,633.18%.\nBXRX operates in the Health Technology sector, specifically in the Pharmaceuticals: Major industry. The next reporting date for BXRX is scheduled for November 13, 2023.\nThe earnings per share (EPS) forecast for this quarter is -$0.92. In the previous year, BXRX reported an annual revenue of $1.3 million.\nThe price-to-earnings (P/E) ratio for BXRX is not available (NM). The price-to-sales ratio is 0.83, which suggests that the stock may be undervalued relative to its sales.\nIn conclusion, BXRX stock had a relatively stable performance on September 28, 2023. The company has shown strong earnings growth in the past year and this year, but has not been profitable. With a negative net profit margin and an anticipated loss for the upcoming quarter, investors should carefully consider the risks associated with investing in BXRX. \n\nBaudax Bio Inc (BXRX) Stock Shows Remarkable Performance on September 28, 2023: Analysts Predict Potential Increase, but Consensus Remains Hold\n BXRX stock had a remarkable performance on September 28, 2023, according to data from CNN Money. The 1 analyst offering a 12-month price forecast for Baudax Bio Inc predicted a median target of $24.00, with both the high and low estimates also at $24.00. This suggests a potential increase of 7,844.39% from the last recorded price of $0.30.\nThe consensus among 1 polled investment analyst is to hold stock in Baudax Bio Inc. This rating has remained unchanged since December when it was downgraded from a buy rating. This indicates that the analyst community is not recommending buying or selling the stock at the moment.\nIt is important to note that the current quarter’s earnings per share for Baudax Bio Inc stood at -$0.92. This indicates that the company had a loss during this period. Additionally, the reported sales for the current quarter were $0.00, suggesting that the company did not generate any revenue during this time.\nInvestors and market participants will eagerly await the reporting date for the current quarter, which is scheduled for November 13. This report will provide further insights into the company’s financial performance and may impact the stock’s future trajectory.\nOverall, BXRX stock had an impressive performance on September 28, 2023, with analysts predicting a significant potential increase in its price. However, the current consensus among analysts is to hold the stock, indicating a cautious approach. Investors should closely monitor the upcoming earnings report to make informed decisions regarding their investment in Baudax Bio Inc. \n\nTags: BXRX","kind":null,"is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.1","shortVersion":"4.29.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2370771770"}